What is he best known for?
The fields of study he is best known for:
- Alzheimer's disease
- Internal medicine
- Pathology
Adam S. Fleisher spends much of his time researching Alzheimer's disease, Dementia, Pathology, Internal medicine and Neuroimaging.
He interconnects Biomarker, Cognition, Neuroscience and Clinical trial in the investigation of issues within Alzheimer's disease.
In his research on the topic of Dementia, Cardiology, Autopsy and Florbetaben is strongly related with Positron emission tomography.
His primary area of study in Pathology is in the field of Presenilin.
The study incorporates disciplines such as Gastroenterology and Surgery in addition to Internal medicine.
His research integrates issues of Alzheimer's Disease Neuroimaging Initiative, Magnetic resonance imaging and Brain mapping in his study of Neuroimaging.
His most cited work include:
- The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. (2619 citations)
- Use of Florbetapir-PET for Imaging β-Amyloid Pathology (789 citations)
- Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study (504 citations)
What are the main themes of his work throughout his whole career to date?
Adam S. Fleisher focuses on Alzheimer's disease, Internal medicine, Disease, Neuroscience and Dementia.
Pathology covers Adam S. Fleisher research in Alzheimer's disease.
His Pathology study combines topics in areas such as Young adult and Positron emission tomography.
His Internal medicine study integrates concerns from other disciplines, such as Endocrinology, Oncology, Brain mapping and Cardiology.
He has researched Disease in several fields, including Clinical trial, Beta and Gerontology.
His work investigates the relationship between Dementia and topics such as Alternative medicine that intersect with problems in Pediatrics.
He most often published in these fields:
- Alzheimer's disease (32.72%)
- Internal medicine (28.40%)
- Disease (24.07%)
What were the highlights of his more recent work (between 2013-2019)?
- Alzheimer's disease (32.72%)
- Cognitive decline (9.26%)
- Neuroscience (24.07%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Alzheimer's disease, Cognitive decline, Neuroscience, Pathology and Dementia.
The Alzheimer's disease portion of his research involves studies in Internal medicine and Disease.
His Cognitive decline research is multidisciplinary, relying on both Psychiatry, Effects of sleep deprivation on cognitive performance and Pediatrics.
His Pathology research includes themes of Biomarker and White matter.
His research investigates the connection with Dementia and areas like Cognitive impairment which intersect with concerns in Brain region, Diagnostic marker and Middle frontal gyrus.
His studies in Neuroimaging integrate themes in fields like Alzheimer's Disease Neuroimaging Initiative, Magnetic resonance imaging, Artificial intelligence and Pattern recognition.
Between 2013 and 2019, his most popular works were:
- Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis (450 citations)
- Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. (324 citations)
- Brain Differences in Infants at Differential Genetic Risk for Late-Onset Alzheimer Disease A Cross-sectional Imaging Study (162 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Alzheimer's disease
- Pathology
Adam S. Fleisher mainly investigates Alzheimer's disease, Cognitive decline, Pathology, Psychiatry and Alzheimer's Disease Neuroimaging Initiative.
His Alzheimer's disease study combines topics from a wide range of disciplines, such as Differential diagnosis and Dementia.
His work carried out in the field of Dementia brings together such families of science as Clinical endpoint, Apolipoprotein E, Physical medicine and rehabilitation and Cognitive test.
His Cognitive decline research focuses on Cognition and how it relates to Severity of illness, Cohort, Neuroimaging and Clinical trial.
His Pathology research is multidisciplinary, incorporating perspectives in Biomarker, Internal medicine and Precuneus.
The Alzheimer's Disease Neuroimaging Initiative study combines topics in areas such as Pathological, Brain mapping and Right entorhinal cortex.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
